Risk factors for fingolimod-induced lymphopenia in multiple sclerosis.

about

Risk factors for fingolimod-induced lymphopenia in multiple sclerosis.

Item

http://www.wikidata.org/entity/Q52677983

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Risk factors for fingolimod-induced lymphopenia in multiple sclerosis.

@en

Risk factors for fingolimod-induced lymphopenia in multiple sclerosis.

@nl

type

Item

label

Risk factors for fingolimod-induced lymphopenia in multiple sclerosis.

@en

Risk factors for fingolimod-induced lymphopenia in multiple sclerosis.

@nl

prefLabel

Risk factors for fingolimod-induced lymphopenia in multiple sclerosis.

@en

Risk factors for fingolimod-induced lymphopenia in multiple sclerosis.

@nl

P1476

Risk factors for fingolimod-induced lymphopenia in multiple sclerosis.

@en

P2093

Akiyuki Uzawa

http://www.w3.org/2001/XMLSchema#string

Hiroki Masuda

http://www.w3.org/2001/XMLSchema#string

Jia Liu

http://www.w3.org/2001/XMLSchema#string

Masahiro Mori

http://www.w3.org/2001/XMLSchema#string

Satoshi Kuwabara

http://www.w3.org/2001/XMLSchema#string

Tomohiko Uchida

http://www.w3.org/2001/XMLSchema#string

P2860

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

Fingolimod for multiple sclerosis.

A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.

Oral fingolimod (FTY720) for relapsing multiple sclerosis.

PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation

Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.

How obesity affects the neutrophil/lymphocyte and platelet/lymphocyte ratio, systemic immune-inflammatory index and platelet indices: a retrospective study.

Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study.

P304

2055217318759692

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/2055217318759692

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ryohei Ohtani

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29497558

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis

P932

5824911

http://www.w3.org/2001/XMLSchema#string